China Zhongji Investment 2022 IPO Project Progress Series (V): Xuanzhu Biology
China Zhongji Investment is a comprehensive investment platform jointly invested and established by well-known private enterprises in Hebei Province, under the support of the CPC Hebei Provincial Committee and the Provincial Government, and under the guidance of the Hebei Provincial Federation of Industry and Commerce. It is managed and operated by seasoned investors and industry experts.
Since its establishment in 2016, China Zhongji Investment, driven by its initial commitment to integrity, has consistently sought long-term certainty amidst short-term uncertainty. Guided by a technology-centric philosophy, it proactively focuses on the future and implements this through flexible yet rigorous systems. For six years, the company has maintained profitability and moved forward with its partners.
Since 2022, three projects of China Zhongji Investment have already passed the review, and several more are in the process. Starting today, we will gradually interpret these high-quality projects, allowing more people to understand what China Zhongji Investment is doing, with the hope of creating a better future together.
On September 26, 2022, the Shanghai Stock Exchange website showed that Xuanzhu Biotechnology Co., Ltd. (referred to as "Xuanzhu Bio" or "the Company")'s IPO on the STAR Market has been accepted.
Today, let's learn more about Xuanzhu Bio.
Xuanzhu Bio is an innovative pharmaceutical company rooted in China with a global vision. It focuses on major diseases such as digestive diseases, tumors, and non-alcoholic fatty liver disease. It is committed to continuously developing and commercializing first-in-class new drugs with core independent intellectual property rights to address unmet clinical treatment needs. The company possesses both small molecule chemical drug and large molecule biologics R&D systems, driving innovation with a dual-engine approach and creating a product pipeline rarely seen in China, simultaneously encompassing small molecule chemical drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and more.
Comprehensive R&D System, Rich Pipeline Layout
Based on cutting-edge scientific discoveries and years of practical experience and accumulation, Xuanzhu Bio has developed more than twenty candidate innovative drug products at different stages. It has also established an independent and complete integrated R&D system, encompassing target validation, innovative drug design and screening, pre-clinical evaluation, development of small and large molecule raw materials and formulations, clinical research, and new drug listing applications. It possesses drug discovery and design platforms such as a small molecule innovative drug design platform, a Mab-Edit antibody glycosylation editing platform, and a Mebs-Ig bispecific antibody editing platform; an animal experiment center, pharmacodynamic evaluation platform, drug ADME evaluation platform, and safety evaluation platform; as well as formulation technology platforms such as spray drying and coprecipitation technology.
As of June 30, 2022, the company has obtained a total of 249 patent rights, including 148 domestic patents and 101 overseas patents, used to support and protect the company's technology.
A profound and comprehensive R&D platform allows the company to more efficiently and reliably control the R&D process, flexibly adjust development strategies, and efficiently promote product development.
World-Class Scientific Team
The company has established a research and development team with solid professional knowledge, rich R&D experience, and excellent comprehensive abilities, with professional backgrounds covering a wide range of fields such as cell biomedicine, clinical medicine, and pharmacology. As of March 31, 2022, the company had 348 R&D personnel, accounting for 83.25% of the total number of employees, including 17 doctors and 145 masters. The company's main management and technical personnel have decades of experience in well-known domestic and international scientific research institutions and pharmaceutical companies, accumulating rich experience in innovative drug industry management and R&D.
Xuanzhu Bio has strong R&D capabilities and an excellent R&D team with a deep understanding of and unique vision for the pharmaceutical industry. It can closely follow market trends, actively deploy in the cutting-edge technology field of innovative drugs, ensure the continuous consolidation and enhancement of the company's technological advantages, and provide talent support for the smooth implementation of this project.
Smooth Clinical Progress, Gradually Emerging Commercial Value
As of June 30, 2022, the company has advanced 7 products to the clinical and subsequent development stages. One product is in the NDA review stage, two are in the Phase III clinical trial stage; one is in the ANDA review stage; and three clinical-stage independently developed products have been transferred or licensed, with the company enjoying upfront payments, milestone payments, and commercialization sales rights. At the same time, the company has a rich reserve pipeline, with more than ten candidate drugs in the pre-clinical R&D stage.
